BEACON Pharmaceuticals Limited introduced Eltrombopag under the brand name of ETP for the treatment of thrombocytopenia.
Eltrombopag (ETP) is approved by USFDA for the following indications-
- Thrombocytopenia in adult and pediatric patients of 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP).
- Thrombocytopenia in patients with chronic hepatitis C.
- Patients with severe aplastic.
ETP (Eltrombopag) is an oral tablet preparation which is available in the strengths of 25mg & 50mg. It product is manufactured in a dedicated oncology facility.